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Activity Evaluation
1. All of the following were criteria for severe 
Clostridium difﬁ  cile–associated disease (CDAD) in the 
current study, except:
A.   One or more intensive care unit admissions in which 
 cile was a major contributor
B.   Prolonged symptoms past 14 days requiring 
intravenous ﬂ  uid replacement
C.   Colectomy or other surgery directly attributed to 
 cile
D.   Intestinal perforation in the setting of C. difﬁ  cile 
infection
2. What was the prevalence of severe CDAD among all 
of the cases of CDAD in the current study?
3. Which of the following patient factors was most 
associated with an increased risk for severe CDAD on 
multivariate analysis of the current study?
A.   Age >70 years
B.   Chemotherapy use
C.   Antimicrobial use
D.   Previous hospital stay
4.  All of the following laboratory factors were 
predictive of an increased risk for CDAD in the current 
study, except:
A.   White blood cell count >20,000 cells/mL
B.   Serum albumin <2.5 g/dL
C.   Creatinine >2 mg/dL
D.   Alanine aminotransferase >40 U/L
1. The activity supported the learning objectives. 
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2. The material was organized clearly for learning to occur.
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3. The content learned from this activity will impact my practice.
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4. The activity was presented objectively and free of commercial bias.
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Identifying  patients  who  are  at  high  risk  for  severe 
Clostridium  difﬁ  cile–associated  disease  (CDAD)  early  in 
the  course  of  their  infection  may  help  clinicians  improve 
outcomes. Therefore, we compared clinical features asso-
ciated with severe versus nonsevere CDAD by retrospec-
tively reviewing records of hospitalized patients whose fecal 
assays were positive for C. difﬁ  cile toxin. Of 336 patients, 
12.2% had severe disease and 10.1% died from all causes. 
Regression modeling showed the following to be signiﬁ  cant-
ly associated with severe CDAD (p<0.05): age >70 years 
(odds ratio [OR] 3.35), maximum leukocyte count >20,000 
cells/mL (OR 2.77), minimum albumin level <2.5 g/dL (OR 
3.44), maximum creatinine level >2 mg/dL (OR 2.47), small 
bowel obstruction or ileus (OR 3.06), and computed tomog-
raphy  scan  showing  colorectal  inﬂ  ammation  (OR  13.54). 
These clinical and laboratory markers for severe disease 
may be useful for identifying patients at risk for serious out-
comes or death.
T
he incidence and severity of Clostridium difﬁ  cile–asso-
ciated disease (CDAD) is increasing in North America 
(1–3) and Europe (4,5). During the past 10 years in the 
United States, prevalence, case-fatality rates, total attribut-
able mortality rates, and colectomy rates for persons with 
CDAD have markedly increased (6). Acquisition of C. dif-
ﬁ  cile and the development of severe CDAD is associated 
primarily  with  healthcare,  although  community-acquired 
severe disease among persons previously thought to be at 
low risk for infection have been reported (5,7,8). Several 
mechanisms for increased disease severity have been pro-
posed, including emergence of speci? c strains with genetic 
polymorphisms that encode higher levels of bacterial tox-
ins A and B and the production of a binary toxin (3,9,10).
The Centers for Disease Control and Prevention has re-
ported outbreaks of CDAD associated with the new BI/
NAP1 strain in 40 of 50 US states, although the association 
Clinical Risk Factors for Severe 
Clostridium difﬁ  cile–associated 
Disease
Timothy J. Henrich, Douglas Krakower, Asaf Bitton, and Deborah S. Yokoe
  5 1 4   9 0 0 2   h c r a M   , 3   . o N   , 5 1   . l o V   •   d i e / v o g . c d c . w w w   •   s e s a e s i D   s u o i t c e f n I   g n i g r e m E  
Author afﬁ  liations: Brigham and Women’s Hospital, Boston, Mas-
sachusetts, USA (T.J. Henrich, D. Krakower, A. Bitton, D.S. Yokoe); 
Massachusetts General Hospital, Boston (D. Krakower); and Har-
vard Medical School, Boston (Deborah S. Yokoe)
DOI: 10.3201/eid1503.080312
CME ACTIVITY
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity 
to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation
Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is 
accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. Medscape, LLC designates
this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the 
extent of their participation in the activity. All other clinicians completing this activity will be issued a certi? cate of participation. To participate 
in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/
or complete the evaluation at http://www.medscape.com/cme/eid; (4) view/print certi? cate.
Learning Objectives
Upon completion of this activity, participants will be able to:
Identify the criteria used to de? ne severe  •  Clostridium difﬁ  cile–associated disease (CDAD) in the current study
Specify the prevalence of severe CDAD in the current study • 
Identify the clinical risk factors for severe CDAD • 
List the laboratory risk factors for severe CDAD • 
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